Kayla holds over 6 years of experience in the rehab space, including in-house content management at a leading treatment center. She believes addiction and mental health issues are universal human experiences that can serve as important entry points onto a path toward self-realization and well-being.
Kayla holds over 6 years of experience in the rehab space, including in-house content management at a leading treatment center. She believes addiction and mental health issues are universal human experiences that can serve as important entry points onto a path toward self-realization and well-being.
You might have heard the term “zombie drug” in news reports or conversations about the drug crisis. This nickname refers to xylazine, a veterinary sedative that’s increasingly showing up in street drugs, especially fentanyl.
While the “zombie” label grabs attention, it doesn’t tell the whole story. Xylazine is creating serious health challenges for people who often don’t realize their drugs have been adulterated. Understanding what xylazine is, how it affects the body, and why it’s become so common can help you recognize the signs and know how to respond.
If someone you care about uses drugs, or if you’re concerned about your own substance use, learning about xylazine could be lifesaving information. Here’s what you need to know about this drug and how to get help.
Addiction researchers point out that sensationalizing xylazine by portraying users as zombies only adds to the trauma that people struggling with addiction are already facing:
Zombies are cinematically depicted as soulless, dangerous, and required to be killed off entirely for public safety, making the ‘zombie’ analogy especially grave amid the fatal overdose crisis. Xylazine is called the ‘zombie drug’ due to its heavy sedative effect and associated severely infected skin ulcers. We surmise that wide-scale media framing of xylazine as the “zombie drug” has increased stigmas1 onto people who use drugs as their likening to zombies reifies subhuman status.
The skin ulcers caused by xylazine require specialized medical care, which people are less likely to seek if stigma is a barrier. “Xylazine’s proliferation in the illicit drug market will likely increase infected ulcers needing medical attention. People who use drugs are often reluctant to seek medical care due to experiences of medically institutionalized stigma,” say authors of a paper on media framing around xylazine.1 Instead, we should focus on addressing these concerns with compassion and care.
Learn more about undoing stigmatizing language in our interview with Licensed Professional Counselor Andrew J. Schreier.
Also known as “tranq,” xylazine is a powerful sedative used by veterinarians to calm large animals like horses during medical procedures. Recently, it’s been showing up in street drugs, often mixed with opioids like fentanyl without users’ knowledge. Public health officials are concerned because many people don’t realize they’re being exposed to this additional substance. According to the DEA, xylazine is “commonly encountered in combination with fentanyl2 but has also been detected in mixtures containing cocaine, heroin, and a variety of other drugs.” People sometimes use tranq on its own, but this is less common.
Tranq is increasingly found in the illicit drug supply, following the same geographic spread pattern as fentanyl. It first appeared in 2006, gained popularity in the mid-2010s starting in Philadelphia, then spread throughout the East Coast, South, and eventually to the Western U.S. DEA lab analysis shows dramatic increases in xylazine presence between 2020–2021:2 103% in the Northeast, over 1,000% in the South, and significant jumps in the Midwest (516%) and West (750%).
The drug’s prevalence has grown so extensive in some areas that users no longer have a choice about exposure. Xylazine use now extends beyond U.S. borders, with Mexico3 and Scotland both issuing health warnings in early 2024 following a wave of overdose deaths3 linked to the substance.
Several factors contribute to tranq’s popularity in opioid-affected regions. Unlike many controlled substances, xylazine isn’t regulated5 in most places and can be purchased legally for veterinary use, making it easily accessible. Its low cost2—as little as $6–20 per kilogram from online suppliers—allows drug makers to stretch more expensive opioids while maintaining similar sedating effects.
Some people also seek out xylazine-containing drugs because the effects last longer than opioids alone, though this extended high increases overdose risks since xylazine can’t be reversed by naloxone.
Xylazine can seriously affect your physical and mental health, and it’s important to know when to seek medical care. Even if you’re not ready to stop using drugs completely, healthcare providers can help treat these conditions and prevent them from getting worse.
Xylazine is a central nervous system depressant that can cause intense drowsiness, confusion, difficulty focusing, problems with coordination, severely slowed breathing (especially dangerous when combined with opioids), dangerously low blood pressure, and reduced body temperature and heart rate.
One of the most serious long-term effects is xylazine’s impact on skin and tissue health.6 Even brief exposure can cause painful wounds that appear suddenly, worsen quickly, often show up on arms and legs, and require specialized medical care. These wounds can become infected if left untreated, and in severe cases may lead to necrosis or other complications that require amputation. However, healthcare providers are learning more about effective treatment approaches,7 and early intervention can help prevent serious complications.
If you notice any wounds or skin changes, don’t wait to get them checked out. Be honest with medical professionals about possible xylazine exposure so they can give you the right care. Many communities now have specialized wound care services that work with people who use drugs and provide care without judgment.
Learn more about harm reduction strategies that can help keep you safer.
The combination of xylazine and opioids—both dangerous drugs in their own right—poses serious overdose risks. Xylazine amplifies the respiratory-depressant effects of opioids, making it easier to stop breathing entirely. Emergency responders often struggle to revive people who overdose on this drug, as opioid-reversal drugs like naloxone do not affect xylazine. Barber explains the risks this poses for people who use street opioids:
Because xylazine is a sedative and not an opioid,5 overdose reversal medications like Narcan don’t address the drug’s major risks, which include dangerously lowering users’ blood pressure, heart rates and respirations. Those who ingest tranq as part of a fentanyl dose often lapse into hours-long blackouts; by the time they rouse themselves, the effects of the high have worn off, and the desperation for a new dose begins. The CDC still recommends the use of Narcan in suspected intoxications involving xylazine, because it’s so often combined with opioids like fentanyl and heroin.
While authorities in the U.S. have started to grasp the seriousness of this crisis, they didn’t fully understand its breadth and depth due to a lack of accurate data. It is, however, clear that an antidote is urgently needed—which is why scientists are developing a vaccine to block xylazine’s toxic effects.8 So far, the vaccine has been tested on animals with promising results, say chemical biologists at Scripps Research.
One of the biggest challenges with xylazine is that many people don’t know when they might be exposed to it. Illegal drugs are notorious for being unregulated and inconsistent, and xylazine is no exception. It’s often mixed into drugs without users’ knowledge, the amount of tranq present in opioids like fentanyl can vary significantly from one batch or dose to another, and standard drug testing methods don’t detect it. This increases the risk of overdose and other adverse side effects. It’s possible for opioid users to become addicted to xylazine9 before they even realize what they’re taking.
Addiction professionals are concerned about xylazine because it complicates overdose response. While naloxone is still essential for reversing opioid overdoses, it doesn’t affect xylazine. This means:
Whether you’re ready to make changes in your drug use or just need help with immediate health concerns, help is available. Healthcare providers increasingly understand how xylazine affects people and can offer:
Seeking help might seem daunting, but numerous resources are available:
If you or someone you know is struggling with addiction, help is available. Search for a rehab center that fits your needs and speak to an addiction specialist today.
A: This term typically refers to street drugs that combine xylazine with synthetic opioids like fentanyl. This combination is dangerous because both substances depress breathing and heart rate, and xylazine cannot be reversed with naloxone.
A: Xylazine was first synthesized in 1962 by Bayer11 for veterinary use as an animal sedative. It began appearing in the illicit drug supply around 2006, with widespread presence developing in the 2010s.
A: Healthcare providers, addiction specialists, wound care teams, and treatment centers can all provide support. Many facilities now offer specialized care for people exposed to xylazine, including medical detox, medication-assisted treatment for opioid components, and wound management services.
A: Media outlets use this term because xylazine causes intense sedation and can lead to severe skin ulcers. However, addiction experts warn that this sensationalized nickname increases stigma and may discourage people from seeking much-needed medical care.
A: Xylazine causes dangerous drops in breathing, heart rate, and blood pressure. It also causes distinctive skin wounds that can appear anywhere on the body, not just injection sites. Combined with opioids, it significantly increases the risk of drug overdose since naloxone doesn’t reverse its effects.
Bowles JM, Copulsky EC, Reed MK. Media framing xylazine as a "zombie drug" is amplifying stigma onto people who use drugs. Int J Drug Policy. 2024 Mar;125:104338. doi: 10.1016/j.drugpo.2024.104338. Epub 2024 Feb 16. PMID: 38364357.
“The Growing Threat of Xylazine and its Mixture with Illicit Drugs.” OCTOBER 2022. US Department of Justice Drug Enforcement Administration. https://www.dea.gov/sites/default/files/2022-12/The%20Growing%20Threat%20of%20Xylazine%20and%20its%20Mixture%20with%20Illicit%20Drugs.pdf
O’Boyle, Brendan. “Mexico Sounds Alarm over ‘zombie Drug’ Sedative in Opioids.” Reuters, 12 Apr. 2024. www.reuters.com, https://www.reuters.com/world/americas/mexico-sounds-alarm-over-zombie-drug-sedative-opioids-2024-04-12/.
Rising concern over New “zombie” Drug in Scotland. 19 Aug. 2024, https://www.bbc.com/news/articles/c24pqrrg8q0o.
Barber, Carolyn. “Tranq, the New ‘Zombie’ Drug That Causes Skin-Rotting, Is Fueling Overdoses across the U.S.” Fortune Well, https://fortune.com/well/2023/03/07/tranq-xylazine-zombie-drug-skin-rotting/.
Srikrishna V. Malayala, et al. "Xylazine-Induced Skin Ulcers in a Person Who Injects Drugs in Philadelphia, Pennsylvania, USA." Cureus. https://assets.cureus.com/uploads/case_report/pdf/98408/20220918-10956-k24th4.pdf
Zagorski, C.M., Hosey, R.A., Moraff, C. et al. Reducing the harms of xylazine: clinical approaches, research deficits, and public health context. Harm Reduct J 20, 141 (2023). https://doi.org/10.1186/s12954-023-00879-7
Developing a Vaccine for the “Zombie Drug” Xylazine. https://www.scripps.edu/news-and-events/press-room/2024/20240403-janda-xylazine.html.
CDC. “What You Should Know About Xylazine.” Overdose Prevention, 17 Jul. 2025, https://www.cdc.gov/overdose-prevention/about/what-you-should-know-about-xylazine.html.
Developing a Vaccine for the “Zombie Drug” Xylazine. https://www.scripps.edu/news-and-events/press-room/2024/20240403-janda-xylazine.html.
"Xylazine." Drug Enforcement Administration Diversion Control Division Drug & Chemical Evaluation Section. https://www.deadiversion.usdoj.gov/drug_chem_info/Xylazine.pdf
We believe everyone deserves access to accurate, unbiased information about mental health and recovery. That’s why we have a comprehensive set of treatment providers and don't charge for inclusion. Any center that meets our criteria can list for free. We do not and have never accepted fees for referring someone to a particular center. Providers who advertise with us must be verified by our Research Team and we clearly mark their status as advertisers.
Our goal is to help you choose the best path for your recovery. That begins with information you can trust.